Pharmacodynamics and Clinical Studies with Beraprost Sodium, a Drug for Peripheral Vascular Disease
1992; Wiley; Volume: 10; Issue: 4 Linguagem: Inglês
10.1111/j.1527-3466.1992.tb00258.x
ISSN1527-3466
Autores Tópico(s)Coagulation, Bradykinin, Polyphosphates, and Angioedema
ResumoCardiovascular Drug ReviewsVolume 10, Issue 4 p. 392-403 Free to Read Pharmacodynamics and Clinical Studies with Beraprost Sodium, a Drug for Peripheral Vascular Disease Satoshi Takeo, Corresponding Author Satoshi Takeo Department of Pharmacology, Tokyo College of Pharmacy, Hachioji, Tokyo, JapanAddress correspondence and reprint requests to Dr. S. Takeo, at Department of Pharmacology, Tokyo College of Pharmacy, 1432-1, Horinouchi, Hachioji, Tokyo 192-03, Japan.Search for more papers by this author Satoshi Takeo, Corresponding Author Satoshi Takeo Department of Pharmacology, Tokyo College of Pharmacy, Hachioji, Tokyo, JapanAddress correspondence and reprint requests to Dr. S. Takeo, at Department of Pharmacology, Tokyo College of Pharmacy, 1432-1, Horinouchi, Hachioji, Tokyo 192-03, Japan.Search for more papers by this author First published: December 1992 https://doi.org/10.1111/j.1527-3466.1992.tb00258.xCitations: 12AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Akiba T, Miyazaki M, Toda N. Vasodilator actions of TRK-100, a new prostaglandin I2 analogue. Br J Pharmacol 1986; 89: 703–711. 2 Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 1990; 75: 329–336. 3 Emson CT. The role of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743–4746. 4 Ferrari R, Cargnoni A, Curello S, Boffa GM, Ceconi C. Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts. Br J Pharmacol 1989; 98: 678–684. 5 Hosokawa T, Yamaguchi M, Kimura S, Miwa K, Okumizu H. Carcinogenicity study of beraprost sodium given to F344 rats in the drinking water. The Clin Report 1989; 23: 3687–3705. 6 Ikeda Y, Uji Y. Effects of beraprost sodium (TRK-100) on platelet aggregation. A single administration test. Modern Med Care 1992; 24: 135–140. 7 Ikeda Y, Uji Y. Effects of beraprost sodium (TRK-100) on platelet adhesion. A single administration test. Modern Med Care 1992; 24: 141–147. 8 Inoue S, Kinoshita M, Toda N. Differential inhibition by vasocilators of coronary artery contraction. Arch Int Pharmacodyn 1988; 295: 181–193. 9 Isaka Y, Handa N, Imaizumi M, Kimura K, Kamada T. Effect of TRK-100, a stable orally active prostacyclin analogue, on platelet function and plaque size in atherothrombotic strokes. Thrombosis and Haemostasis 1991; 65: 344–350. 10 Isaka Y, Edani H, Handa N, et al. Effect of orally active prostacyclin analogue TRK-100 on platelet deposition in carotid atherosclerosis. J Clin Exp Ther 1990; 155: 129–130. 11 Ishii H, Kizaki K, Uchiyama H, Horie S, Kazama M. Cyclic AMP increases thrombomodulin expression on membrane surface of cultured human umbilical vein endothelial cells. Thrombosis Res 1990; 59: 841–850. 12 Kainoh M, Imai R, Umetsu T, Hattori M, Nishio S. Prostacyclin and beraprost sodium as suppresses of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990; 39: 477–484. 13 Kajikawa N, Nogimori K, Murata T, Nishio S, Uchiyama S. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittel forschung 1989; 39(I): 495–499. 14 Katoh R, Uji Y, Matsumoto K. Phase I study of beraprost sodium (TRK-100), a prostacyclin derivative-single oral administration study. Jpn J Clin Pharmacol Ther 1989; 20: 515–527. 15 Katoh R, Uji Y, Matsumoto K. Phase I study of beraprost sodium (TRK-100), a prostacyclin derivative-repeated oral administration study for 10 days. Jpn J Clin Pharmacol Ther 1989; 20: 529–539. 16 Katsumura T, Masaki H. Antiaggregatory effect of TRK-100 (prostaglandin I2 analogue) in chronic arterial occlusive disease. J New Remed Clinics 1989; 38: 1401–1406. 17 Kimura I, Pancho LR, Isoi Y, Kimura M. Diabetic-induced enhancement of prostanoid-stimulated contraction in mesenteric veins of mice. Jpn J Pharmacol 1989; 51: 403–410. 18 Kurihara J, Sahara T, Kato H. Protective effect of beraprost sodium, a new chemically stable prostacyclin analogue, against the deterioration of baroreceptor reflex following transient global ischaemia in dogs. Brit J Pharmacol 1990; 99: 91–96. 19 Kurihara J, Watanabe N, Kato H. Effects of beraprost sodium (TRK-100), anew analogue of prostaglandin I2, on contractions of isolated vas deferens and portal vein. Pharmacometrics 1989; 38: 231–238. 20 Martin JF, Suggett AJ, Leach E, Moncada S. The effect of prostacyclin on platelet aggregation and disaggregation in vivo. Thromb Res 1980; 18: 741–751. 21 Moncada S. Biological importance of prostacyclin. Br J Pharmacol 1982; 76: 3–31. 22 Minami Y, Toda N. Comparison of the response to angiotensin II of isolated dog coronary and mesenteric arteries of proximal and distal portions. Arch Int Pharmacodyn 1988; 293: 186–195. 23 Murai T, Muraoka K, Saga K, et al. Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits. Arzneimiettel forschung 1989; 39(II): 856–859. 24 Murata T, Sakaya S, Hoshino T, Umetsu T, Hirano T, Nishio S. General pharmacology of beraprost sodium. 1st communication: Effect on the central nervous system. Arzneimittel forschung 1989; 39(II): 860–866. 25 Murata T, Murai T, Kanai T, et al. General pharmacology of beraprost sodium. 2nd communication: Effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects. Arzneimiettel forschung 1989; 39(II): 867–876. 26 Nishio S, Matsuura H, Kanai N, et al. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analogue, in several species. Jpn J Pharmacol 1988; 47: 1–10. 27 Nishio S, Matsuura H, Hattori M, Endoh T, Yamada N, Hirano T. Cardiovascular effects of beraprost sodium (TRK-100), a prostacyclin analogue in the dog. Folia Pharmacol Japon 1989; 94: 351–361. 28 Nishio S, Yamada N, Endoh T, et al. Effect of beraprost sodium on peripheral circulatory disturbances induced by various stimuli. Arzneimittel forschung 1989; 39(II): 1229–1234. 29 Ochiai T, Funabashi N, Kobayashi Y, et al. Carcinogeniciry study of beraprost sodium in rats. The Clin Report 1989; 23: 3706–3724. 30 Pi X, Chen X. Arachidonic acid causes postischemic dysfunction in control but not diabetic hearts. Am J Physiol 1990: 258: 1261–1271. 31 Sakaguchi S, Tanabe T, Mishima Y, Shionoya Y, Katsumura T, Kusaba A. Clinical evaluation of prostacyclin derivative, beraprost sodium, in patients with Raynaud's disease and Raynaud's syndrome. Med Consul New Remed 1989; 26: 1516–1529. 32 Sakaguchi S, Tanabe T, Mishima Y, et al. Evaluation of beraprost sodium (PGI2 derivative) in patients with chronic arterial occlusive disease. Double blind test with ticlopidine hydrochloride. Jpn J Clin Exp Ther 1990; 67: 575–584. 33 Sakai A, Hori T, Okuda T, et al. Effect of TRK-100, a prostacyclin analogue, on endotoxin-induced enhancement of blood coagulation in rats. Jpn J Pharmacol 1989; 51: 450–454. 34 Sakai A, Yajima M, Nishio S. Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci 1990; 47: 711–719. 35 Tanabe T, Yasuda Y, Okuyama S, et al. Long-term therapy of chronic arterial occlusive disease with a prostaglandin derivative, beraprost sodium (TRK-100). Modern Med Care 1992; 24: 159–169. 36 Tanonaka K, Maruyama Y, Takeo S. Beneficial effect of beraprost, a prostacyclin-mimetic agent, on post-hypoxic recovery of cardiac function and metabolism in rabbit isolated hearts. Br J Pharmacol 1991; 104: 779–786. 37 Toda N. Beraprost sodium. Cardiovasc Drug Rev 1988; 6: 222–238. 38 Uemichi A, Kakinoki E. Effect of a stable prostacyclin analogue (TRK-100) on peripheral circulation in patients with Raynaud's syndrome. Jpn Pharmacol Ther 1989; 17: 3691–3702. 39 Umetsu T, Murata T, Tanaka Y, Osada E, Nishio S. Antithrombic effect of TRK-100, a novel, stable PGI2 analogue. Jpn J Pharmacol 1987; 43: 81–90. 40 Umetsu T, Murata T, Nishio S. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats. Arzneimittel forschung 1989; 39(I): 68–73. 41 Yamaguchi H, Furukawa K. Effect of PG I2 analogue (TRK-100) on haemorrheological factors in patients with peripheral vascular disease. Blood and Vessel 1989; 20: 147–151. Citing Literature Volume10, Issue4December 1992Pages 392-403 ReferencesRelatedInformation
Referência(s)